GE HealthCare Technologies Inc. Q2 2026 Results
On 29 July 2026, GE HealthCare Technologies Inc. (NASDAQ:GEHC) released its second‑quarter 2026 earnings before the market opened, surpassing Wall Street expectations. Adjusted earnings per share were $1.13, beating the analyst consensus of $1.04 by $0.09. Revenue reached $5.3 billion, exceeding the estimate of $5.26 billion and representing a 5.7% increase over the same quarter a year earlier.
Organic orders grew 11.1% year‑over‑year, delivering a record book‑to‑bill ratio of 1.15 times and pushing the order backlog to $23.9 billion. The organic revenue increase of 3.5% was driven primarily by strength in Pharmaceutical Diagnostics and Advanced Imaging Solutions across the United States, Europe, the Middle East and Africa. In contrast, the Patient Care Solutions segment saw revenue decline 13.5% YoY, which contributed to the adjusted EBIT margin falling 40 basis points to 14.2% year‑over‑year. The margin pressure was further attributed to inflationary impacts from memory chips, oil and freight costs.
Tariff refunds added $129 million to net income and $23 million to adjusted EBIT. Cash flow from operating activities amounted to $168 million, an increase of $74 million versus the prior year, while free cash flow rose to $68 million, up $61 million YoY. Following the release, GE HealthCare shares jumped approximately 9% in pre‑market trading.
President and CEO Peter Arduini said, "We delivered record orders and backlog in the second quarter, with orders growth across every segment, demonstrating strong commercial execution, including the adoption of new products."
The company reaffirmed its full‑year 2026 guidance, projecting organic revenue growth of 3.0% to 4.0%, an adjusted EBIT margin range of 15.4% to 15.7%, and adjusted earnings per share between $4.80 and $5.00. The midpoint of the EPS guidance, $4.90, implies a 6.8% year‑over‑year increase. GE HealthCare also expects free cash flow of approximately $1.6 billion for the full year.